IGMS / IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM , Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a ph more_horizontal

STOCKHOLM, Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innova more_horizontal

STOCKHOLM , Sept. 1, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments fo more_horizontal

STOCKHOLM , Aug. 23, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments fo more_horizontal

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $1. more_horizontal

IGM Biosciences, Inc. (IGMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might more_horizontal

STOCKHOLM , June 1, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for more_horizontal

STOCKHOLM , May 30, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for more_horizontal